NHS patients who are already receiving these medicines for gender incongruence and/or gender dysphoria can continue to access them, as can patients receiving the medicines for other uses.
The annual mortality review commissioned by NHS England was originally meant to be published last year but faced repeated delays. It found 39% of deaths of people with learning disabilities and autism were classed as avoidable in 2023, almost twice as high as the general population. NHS England said it was rolling out more training for staff and identifying patients with learning disabilities earlier so they can be given more "appropriate care".